PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
ED  - Moriarty, Patrick M.
TI  - Novel Therapeutics May Lower LDL in Familial Hypercholesterolemia
DP  - 2013 May 01
TA  - MD Conference Express
PG  - 30--31
VI  - 13
IP  - 2
4099  - http://mdc.sagepub.com/content/13/2/30.short
4100  - http://mdc.sagepub.com/content/13/2/30.full
AB  - Familial combined hyperlipidemia is a highly atherogenic disorder that affects 1% to 2% of the Western world [Shoulders CC et al. Hum Mol Genet 2004]. It occurs in approximately 20% of patients who develop coronary heart disease before age 60 [Aouizerat BE et al. Am J Hum Genet 1999]. This article discusses the need for continued research of treatments for familial hypercholesterolemia (FH). Emerging therapies include apolipoprotein B (ApoB) inhibitors, microsomal triglyceride transfer protein (MTP) inhibitors, and proprotein convertase subtilism kexin 9 (PCSK9) inhibitors [Alonso R et al. Expert Rev Cardiovasc Ther 2013].